48 patents
Page 2 of 3
Utility
Dosage regimes for the administration of an anti-CD19 ADC
3 May 22
The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs).
Jay Marshall Feingold, David Rodney Ungar
Filed: 14 Jun 18
Utility
Molecular Adjuvant
14 Apr 22
The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed.
Patrick Hendrikus Cornelis VAN BERKEL, Jay Marshall FEINGOLD, Jens WUERTHNER, James ADAMS
Filed: 22 May 19
Utility
Pyrrolobenzodiazepine-antibody Conjugates and Uses Thereof
31 Mar 22
The present disclosure relates to novel pyrrolobenzodiazepine antibody-drug conjugates (PBD-ADCs) and therapeutic uses thereof.
Patricius Hendrikus Cornelis van Berkel, Persis Amrolia, Kerry Chester, Jenny Yeung
Filed: 22 Sep 21
Utility
ANTI-IL13R ALPHA2 Antibodies
3 Feb 22
This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13Rα2) protein, and associated uses and methods for production.
Patricius Hendrikus Cornelis Van Berkel, Francois Bertelli
Filed: 30 Jul 21
Utility
Combination Therapy with an ANTI-CD25 Antibody-drug Conjugate
20 Jan 22
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
Filed: 20 Apr 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
20 Jan 22
The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 20 Jul 21
Utility
Pyrrolobenzodiazepine-antibody Conjugates
13 Jan 22
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 24 Sep 21
Utility
Pyrrolobenzodiazepine-antibody conjugates
2 Nov 21
Patricius Hendrikus Cornelis Van Berkel
Filed: 8 Feb 18
Utility
Combination Therapy
21 Oct 21
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Francesca ZAMMARCHI, Francesco BERTONI
Filed: 30 Aug 19
Utility
Method for treating breast cancer
10 Aug 21
Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety.
Gilles Bernard Tremblay, Anna N. Moraitis, Mario Filion
Filed: 18 Oct 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
22 Apr 21
The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD, John HARTLEY
Filed: 28 Aug 20
Utility
Pyrrolobenzodiazepine-antibody Conjugates
1 Apr 21
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 8 Feb 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
18 Mar 21
The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
Patricius Hendrikus Cornelis VAN BERKEL
Filed: 8 Feb 18
Utility
Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof
25 Feb 21
Antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein.
Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
Filed: 9 Dec 19
Utility
Dosage Regimes for the Administration of an ANTI-CD25 Adc
30 Dec 20
Jay Marshall Feingold, Jens Wuerthner
Filed: 13 Jun 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
30 Dec 20
The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.
Jay Marshall FEINGOLD, Patricius Hendrikus Cornelis VAN BERKEL
Filed: 1 Mar 20
Utility
Combination Therapy
30 Dec 20
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer.
Jay Marshall Feingold, Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
Filed: 19 Apr 18
Utility
Pyrrolobenzodiazepine-antibody Conjugates
30 Dec 20
Conjugates of an antibody that binds to CD25 with PBD dimers.
PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
Filed: 18 Aug 20
Utility
Site-specific Antibody-drug Conjugates
23 Dec 20
Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker.
Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD
Filed: 13 Nov 19
Utility
Pyrrolobenzodiazepine-antibody conjugates
12 Oct 20
Conjugates of an antibody that binds to CD25 with PBD dimers.
Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
Filed: 4 Mar 18